ELVN
Enliven Therapeutics, Inc.Company Information
- Company Name
- Enliven Therapeutics, Inc.
- CIK
- CIK0001672619
- Category
- Non-accelerated filer
- Ticker: Exchange
- ELVN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ELVN
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-17
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 1,754,017
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 76,921,999
- Shares outstanding
- 66,171,581
- Ownership
- 116.25%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- -3.08%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 136 | 132 | 99 | 102 | 119 | 102 | 124 | 101 | 97 | 149 | 100 | 74 | ||||||
| Marketable Securities Current | 760 | 320 | 364 | 376 | 371 | 188 | 189 | 191 | 216 | 171 | 153 | 190 | ||||||
| Restricted Cash Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 12 | 11 | 12 | 5 | 5 | 5 | 5 | 5 | 6 | 7 | 3 | 5 | ||||||
| Assets Current | 907 | 463 | 475 | 483 | 496 | 294 | 318 | 297 | 318 | 337 | 266 | 269 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 7 | 7 | 7 | 7 | 7 | 8 | 4 | 4 | 4 | ||||||
| Assets | 910 | 465 | 476 | 491 | 504 | 303 | 326 | 305 | 327 | 343 | 272 | 274 | ||||||
Liabilities Current | ||||||||||||||||||
| Restricted Cash Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Accounts Payable Current | 0 | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | ||||||
| Liabilities Current | 14 | 11 | 17 | 15 | 15 | 14 | 16 | 17 | 22 | 25 | 26 | 12 | ||||||
| Other Liabilities Noncurrent | 1 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 15 | 11 | 17 | 15 | 15 | 14 | 16 | 17 | 22 | 25 | 26 | 12 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,300 | 824 | 806 | 793 | 786 | 560 | 553 | 508 | 502 | 495 | 400 | 397 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -403 | -371 | -347 | -317 | -297 | -272 | -243 | -220 | -197 | -177 | -154 | -135 | ||||||
| Stockholders Equity | 895 | 453 | 460 | 476 | 488 | 288 | 310 | 288 | 305 | 318 | 246 | 262 | ||||||
| Liabilities And Stockholders Equity | 910 | 465 | 476 | 491 | 504 | 303 | 326 | 305 | 327 | 343 | 272 | 274 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Common Stock Shares Authorized | 200 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 73 | 61 | 59 | 59 | 59 | 49 | 49 | 47 | 47 | 47 | 41 | 41 | ||||||
| Shares Outstanding | 73 | 61 | 59 | 59 | 59 | 49 | 49 | 47 | 47 | 47 | 41 | 41 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialEnliven Therapeutics, Inc. (ELVN) — SEC Financial Statements & Analysis
Enliven Therapeutics, Inc. (ELVN) is a pharmaceutical preparations company, incorporated in DE. Enliven Therapeutics, Inc. trades on Nasdaq as: ELVN. Enliven Therapeutics, Inc. (ELVN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Enliven Therapeutics, Inc. carries a market cap of $3.36B, a P/E ratio of -31.70x, a P/B ratio of 3.75x, an enterprise value of $3.22B, and an EV/EBITDA multiple of -25.93x. On profitability, it posts a Return on Equity (ROE) of -15.31%, a Return on Assets (ROA) of -14.98%, and a Return on Invested Capital (ROIC) of -22.05%. Per share, it reports EPS of $-1.60, diluted EPS of $-1.60, free cash flow per share of $-1.01, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 5.70% year-over-year and EPS growth of -16.77% year-over-year. On the balance sheet, it maintains a current ratio of 64.07x, a quick ratio of 63.21x, working capital of $893.18M, a debt-to-equity ratio of 0.02x, a debt ratio of 0.02, an interest coverage ratio of -6.73x, free cash flow of $-67.04M (TTM), and net debt of $-135.50M. Figures sourced from SEC EDGAR.
- Market Cap
- $3.36B
- P/E TTM
- -31.70x
- EPS TTM
- $-1.60
- P/B TTM
- 3.75x
- ROE TTM
- -15.31%
- ROA TTM
- -14.98%
- Debt To Equity
- 0.02x
- Free Cash Flow TTM
- $-67.04M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Enliven Therapeutics, Inc. in?
Enliven Therapeutics, Inc. (ELVN) operates in the Pharmaceutical Preparations industry.
What exchange does ELVN trade on?
Enliven Therapeutics, Inc. (ELVN) trades on the Nasdaq.
Where is Enliven Therapeutics, Inc. incorporated?
Enliven Therapeutics, Inc. is incorporated in DE.
When was Enliven Therapeutics, Inc. (ELVN)'s most recent SEC filing?
Enliven Therapeutics, Inc. (ELVN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is ELVN's market cap?
Enliven Therapeutics, Inc. (ELVN) has a market capitalization of $3.36B as of 2026-06-30.
What is ELVN's EPS (earnings per share)?
Enliven Therapeutics, Inc. (ELVN)'s trailing twelve month EPS is $-1.60 as of 2026-06-30.
What is ELVN's ROE (return on equity)?
Enliven Therapeutics, Inc. (ELVN)'s trailing twelve month Return on Equity (ROE) is -15.31% as of 2026-06-30.
What is ELVN's ROA (return on assets)?
Enliven Therapeutics, Inc. (ELVN)'s trailing twelve month Return on Assets (ROA) is -14.98% as of 2026-06-30.
What is ELVN's ROIC (return on invested capital)?
Enliven Therapeutics, Inc. (ELVN)'s trailing twelve month Return on Invested Capital (ROIC) is -22.05% as of 2026-06-30.
What is ELVN's EV/EBITDA?
Enliven Therapeutics, Inc. (ELVN)'s trailing twelve month EV/EBITDA is -25.93x as of 2026-06-30.